Litchfield Hills Research Weighs in on ADIL FY2025 Earnings

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) – Litchfield Hills Research increased their FY2025 EPS estimates for shares of Adial Pharmaceuticals in a report released on Tuesday, December 9th. Litchfield Hills Research analyst T. O’neill now forecasts that the company will post earnings per share of ($0.48) for the year, up from their previous forecast of ($0.53). The consensus estimate for Adial Pharmaceuticals’ current full-year earnings is ($1.53) per share. Litchfield Hills Research also issued estimates for Adial Pharmaceuticals’ Q4 2025 earnings at ($0.07) EPS, Q1 2026 earnings at ($0.06) EPS, Q2 2026 earnings at ($0.07) EPS, Q3 2026 earnings at ($0.07) EPS, Q4 2026 earnings at ($0.07) EPS and FY2026 earnings at ($0.26) EPS.

Other equities research analysts have also issued research reports about the company. Maxim Group raised Adial Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.50 price target on the stock in a research report on Tuesday, September 30th. Zacks Research cut shares of Adial Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 20th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Adial Pharmaceuticals in a report on Wednesday, October 8th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $1.50.

Adial Pharmaceuticals Trading Down 0.5%

NASDAQ:ADIL opened at $0.30 on Friday. Adial Pharmaceuticals has a 12-month low of $0.22 and a 12-month high of $1.30. The firm has a market cap of $7.09 million, a PE ratio of -0.39 and a beta of 1.11. The stock has a fifty day moving average price of $0.34 and a 200 day moving average price of $0.38.

Adial Pharmaceuticals (NASDAQ:ADIL) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.01.

Hedge Funds Weigh In On Adial Pharmaceuticals

A hedge fund recently bought a new stake in Adial Pharmaceuticals stock. Citadel Advisors LLC acquired a new position in shares of Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 143,791 shares of the company’s stock, valued at approximately $51,000. Citadel Advisors LLC owned approximately 0.60% of Adial Pharmaceuticals at the end of the most recent quarter. Institutional investors own 16.41% of the company’s stock.

Adial Pharmaceuticals Company Profile

Adial Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.